Molecule Name |
DB08871
|
DrugBank Groups |
Approved
|
Cluster No |
549
|
Smiles |
O=C6(CC5(OC4(C1(OC2(OC3(C(C1OC3(C2))OC4CC5))(CCC9(OC(CCC8(OC(CC7(C(C6)C(OC)C(CC(O)CN)O7))C(=C)C(C)C8))C(=C)C9))))))
|
Download |
mol2, pdbqt
|
TPSA |
146,39
|
Non-H Atoms |
52
|
Non-C/H Atoms |
12
|
Metal-Atoms |
0
|
Electronegative Atoms |
12
|
Stereo Centers |
19
|
Rotatable Bonds |
4
|
Rings Closures |
9
|
Small Rings |
9
|
Aromatic Rings |
0
|
Aromatic Atoms |
0
|
sp3-Atoms |
46
|
Symmetric atoms |
0
|
cLogS |
-6,523
|
MW |
729,904
|
cLogP |
1,5381
|
HBA |
12
|
HBD |
2
|
Ro5 violations |
2
|
Druglikeness |
-2,9568
|
DrugScore |
0,161384161644507
|
Mutagenic |
none
|
Tumorigenic |
none
|
Reproductive Effective |
none
|
Irritant |
none
|
Blood-Brain Barrier |
BBB-
|
Human Intestinal Absorption |
HIA+
|
Caco-2 Permeability |
Caco2-
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Inhibitor
|
P-glycoprotein Inhibitor 2 |
Non-inhibitor
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Aqueous solubility |
-3,4165
|
Caco-2 Permeability 2 |
-0,1104
|
Subcellular localization |
Mitochondria
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 2D6 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP Inhibitory Promiscuity |
Low CYP Inhibitory Promiscuity
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition 2 |
Inhibitor
|
AMES Toxicity |
Non AMES toxic
|
Carcinogens |
Non-carcinogens
|
Fish Toxicity |
High FHMT
|
Fish Toxicity (pLC50, mg/L) |
0,9438
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity (pIGC50, ug/L) |
0,5924
|
Honey Bee Toxicity |
High HBT
|
Biodegradation |
Not ready biodegradable
|
Acute Oral Toxicity |
III
|
Rat Acute Toxicity (LD50, mol/kg) |
2,9429
|
Carcinogenicity (Three-class) |
Non-required
|